Search results
Dec 8, 2020 · SHANGHAI and SYDNEY, 8 December 2020 – Novotech Health Holdings (“Novotech Holdings”), the largest biotech specialist contract research organization (CRO) in Asia, today announced the appointment of Anand Tharmaratnam as Chairman of the Board commencing 1 April 2021.
- Korean
2020년 12월 8 일 상하이 및 시드니 – 아시아 최대 생명공학 임상시험수탁기관(CRO)인...
- Chinese, Simplified
上海和悉尼，2020年12月8日——亚洲优秀的生物技术专业合同研究组...
- Chinese, Traditional
Anand Tharmaratnam said, “Novotech Holdings has developed a...
- Our Management
Anand brings over 20 years of experience in global drug...
- Dr. Anand Tharmaratnam
Dr. Anand Tharmaratnam. Anand brings over 20 years of...
- Korean
View Anand Tharmaratnam’s profile on LinkedIn, a professional community of 1 billion members. Anand is a seasoned healthcare executive with 26 years of industry...
- 500+
- 1.1K
- Royal College of Anaesthetists
- Novotech Health Holdings
Anand brings over 20 years of experience in global drug development and the CRO industry. He was previously the president of Asia Pacific at IQVIA. Anand is a medical doctor by training and graduated from the University College London, UK and trained in the anaesthesia.
Dr. Anand Tharmaratnam. Anand brings over 20 years of experience in global drug development and the CRO industry. He was previously the president of Asia Pacific at IQVIA. Anand is a medical doctor by training and graduated from the University College London, UK and trained in the anaesthesia.
Dr. Anand Tharmaratnam is Senior Vice President and Head of Asia Markets, Clinical Development for Quintiles. In this role, Dr. Tharmaratnam has responsibility for the
Novotech Health Holdings, a major biotech specialist contract research organisation (CRO) in Asia, has appointed Anand Tharmaratnam as Chairman of the Board commencing 1 April 2021. Dr Tharmaratnam brings over 23 years of experience in global drug development and the CRO industry.
Dec 8, 2020 · Novotech Health Holdings, the contract research organization (CRO) in Asia, named Anand Tharmaratnam as Chairman of the Board commencing 1 April 2021. Dr Tharmaratnam brings over 23 years experience in global drug development and the CRO industry.
